Hakozaki Taiki, Kitazono Miyako, Takamori Mikio, Kiriu Takahiro
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan.
Department of Respiratory Medicine and Medical Oncology, Tokyo Metropolitan Tama Medical Center, Japan.
Intern Med. 2020 May 15;59(10):1291-1294. doi: 10.2169/internalmedicine.3542-19. Epub 2020 Feb 26.
Histologic transformation has been described as an acquired mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). We herein report the case of a woman with stage IV lung adenocarcinoma harboring EGFR exon 19 deletions who was initially treated with EGFR-TKIs; several cytotoxic chemotherapeutic regimens were used when resistance developed. A lymph node re-biopsy revealed histologic transformation of the tumor to combined small-cell lung cancer and squamous cell carcinoma with retained EGFR exon 19 deletions. Following sequential chemotherapy appropriate for transformed histology, a clinical response was achieved.
组织学转化已被描述为对表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKIs)产生耐药的一种获得性机制。我们在此报告一例IV期肺腺癌女性患者,该患者存在EGFR第19外显子缺失,最初接受EGFR-TKIs治疗;耐药发生后使用了几种细胞毒性化疗方案。淋巴结再次活检显示肿瘤组织学转化为小细胞肺癌和鳞状细胞癌合并存在,EGFR第19外显子缺失依然存在。采用适合转化后组织学类型的序贯化疗后,取得了临床缓解。